A recent clinical study conducted in Denmark has found that the obesity medication Wegovy, developed by Novo Nordisk A/S, may help reduce alcohol consumption among individuals with alcoholism. The controlled trial involved 108 participants seeking treatment for their addiction, marking one of the first systematic investigations into the drug’s potential benefits for this condition.

After six months of treatment with Wegovy, volunteers reported a significant decrease in heavy drinking days, averaging about five days of heavy alcohol use per 30-day period. This represented a reduction of 12 fewer heavy drinking days compared to their drinking patterns prior to beginning the medication. Alongside this improvement, participants also showed favorable changes in other indicators of alcohol dependence, including overall alcohol intake and relevant biomarkers measured through blood tests.

The findings provide the strongest clinical evidence to date supporting anecdotal accounts that some obesity medications, such as Wegovy, might aid in reducing alcohol consumption. Despite these promising results, Novo Nordisk has not actively pursued large-scale clinical trials specifically targeting alcoholism. Researchers conducting the Danish study noted that they are continuing this line of inquiry largely without direct support from the pharmaceutical company.

These developments highlight a growing interest within the medical community to explore the broader applications of obesity drugs beyond weight management, particularly in the treatment of addictive behaviors. Further research is likely needed to clarify the mechanisms by which Wegovy influences alcohol use and to confirm its safety and efficacy in this new context.